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Activation of the inducible caspase 9 (iC9) safety gene 
by a dimerizing drug (chemical inducer of dimerization 
(CID) AP1903) effectively resolves the symptoms and 
signs of graft-versus-host disease (GvHD) in haploiden-
tical stem cell transplant (HSCT) recipients. However, 
after CID treatment, 1% of iC9-T cells remain and can 
regrow over time; although these resurgent T cells do 
not cause recurrent GvHD, it remains unclear whether 
repeat CID treatments are a safe and feasible way to 
further deplete residual gene-modified T cells should 
any other adverse effects associated with them occur. 
Here, we report a patient who received an infusion of 
haploidentical iC9-T cells after HSCT and subsequently 
received three treatments with AP1903. There was a 
mild (grade 2) and transient pancytopenia following 
each AP1903 administration but no non-hematological 
toxicity. Ninety five percent of circulating iC9-T cells 
(CD3+CD19+) were eliminated after the first AP1903 
treatment. Three months later, the residual cells had 
expanded more than eightfold and had a lower level 
of iC9 expression. Each repeated AP1903 administra-
tion eliminated a diminishing percentage of the residual 
repopulating cells, but elimination could be enhanced 
by T-cell activation. These data support the safety and 
efficiency of repeated CID treatments for persistent or 
recurring toxicity from T-cell therapies.
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INTRODUCTION
Although adoptive cellular immunotherapy can be an effective 
therapeutic strategy to treat human malignancies, the adverse 
effects may be both severe and prolonged. After allogeneic stem 
cell transplantation, for example, adoptive transfer of T cells to 
accelerate immune reconstitution and antiviral immunity can 
produce progressive and fatal acute and chronic graft-versus-host 
disease (GvHD), while transfer of tumor-directed T cells can lead 
to a fatal cytokine release syndrome or to on-target/off-tumor 
or off-target events that may be both rapid in onset and fatal in 
outcome.1–7 As a consequence, there is increasing interest in devel-
oping safety or suicide systems that can address this panoply of 
adverse events by rapidly, reliably, and fully eliminating the T cells 
producing the unwanted events.
The herpes simplex virus thymidine kinase (HSV-tk) suicide 
gene system has previously been used as a safety system since 
it allows T cells to be ablated by the administration of prodrugs 
such as ganciclovir. However, activation of HSV-TK by ganciclo-
vir is relatively slow, and administration of ganciclovir to treat 
cytomegalovirus (CMV) infections would result in unwanted 
destruction of HSV-TK expressing cells. We have previously 
described an approach based on the expression of an inducible 
human caspase 9 transgene (iC9), which is dimerized and hence 
activated by the administration of an otherwise bioinert small 
molecule drug, AP1903.8–10 Since no monoclonal antibody is 
available to detect iC9, we monitored the infused iC9-T cells 
in vivo by generating a retroviral vector encoding iC9 in com-
bination with a truncated CD19 linked by a 2A sequence to use 
as a selectable and trackable marker. Our preclinical and clini-
cal analyses have shown close concordance between changes 
in levels of CD3+CD19+ expression and iC9 transgene expres-
sion.11–13 This iC9 safety switch is human derived, has limited 
immunogenicity, and allows patients to receive ganciclovir and 
related drugs to treat viral infections without T-cell damage. 
Activation of iC9 eradicates up to 99% of iC9-expressing T cells 
(iC9-T  cells) in vitro and in vivo within 2 hours of a single 
dose of the chemical inducer of dimerization (CID AP1903), 
and even a single dose of dimerizing drug to activate the iC9 
transgene can produce sufficient in vivo allodepletion of GvHD-
inducing T cells.11,13,14,15
Although a single dose of dimerizing drug can effectively 
control GvHD, we observed that the small remaining fraction 
of iC9-T cells can subsequently expand and repopulate patients. 
Although such resurgence does not lead to a recurrence of GvHD, 
it currently remains unclear whether we could continue to deplete 
cells in vivo should other adverse effects associated with adoptive 
transfer of T cells occur, and it is unknown whether multiple doses 
of CID could have unanticipated toxicity. Here, we evaluated the 
feasibility and safety of multiple treatments with dimerizing drug 
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RESULTS
Patient details
The patient was an 8-year-old male who received a haploidentical 
stem cell transplant (HSCT) with CD34+ selected stem cells from 
his mother to treat acquired hemophagocytic lymphohistiocytosis 
with central nervous system involvement. Prior to HSCT, he had 
received long-term steroid treatment for his primary disease, and 
his early post-transplant course was complicated by reactivation 
of multiple viruses (CMV, human herpesvirus 6 (HHV6), adeno-
virus (AdV), BK virus (BKV), and Epstein–Barr virus (EBV)), 
persistent transaminitis, and steroid-induced hypertension and 
hyperglycemia. He was enrolled on the DOTTI (Administration 
of haploidentical DOnor T cells Transduced with the Inducible 
caspase-9 suicide gene) study in which patients received escalat-
ing doses of iC9-T cells post HSCT in order augment immune 
reconstitution.15 On day 47 post HSCT, he received 1 × 106 iC9-T 
cells/kg. He had no immediate adverse effects from the T-cell infu-
sions, and within 1–10 weeks, reactivations of CMV, HHV6, AdV, 
and BKV were successfully controlled as judged by polymerase 
chain reaction (PCR) analyses for viral DNA in blood (Table 1).
Three months after administration of iC9-T cells, however, the 
patient was admitted with gastritis. A gastric biopsy was positive by 
PCR for EBV, HHV6, and HHV7, but there was no histological evi-
dence of GvHD. As his EBV load in blood was also elevated, he was 
treated with Rituximab (Table 1). During this admission, he devel-
oped a skin rash, and biopsy was consistent with GvHD (grade 2). 
He was given a single dose of iC9 dimerizer drug AP1903 (#1), 
and his rash had completely resolved within 24 hours. Over the 
next 4–6 weeks, his gastritis also resolved. However, 3 weeks later, 
his hepatic transaminases became elevated although bilirubin and 
alkaline phosphatase remained normal. Circulating iC9-T  cells 
(detected as the CD3+CD19+ population) remained below pre-
dimerizer drug levels (220/µl: Figure 1: #1), but the possibility that 
the infused T cells may have contributed to a possible flare of acute 
GvHD was nonetheless considered. He therefore received two 
additional doses of the dimerizing drug (Figure 1: #2, #3) at inter-
vals of 48 hours. Retreatment had no effect on his transaminitis, 
which was also unresponsive to intensive subsequent immunosup-
pression. A repeat liver biopsy 5 weeks later showed macrovesicu-
lar steatosis compatible with drug therapy and parenteral nutrition 
to which his transaminitis was attributed since he had no evidence 
of acute or chronic GvHD. Unfortunately, in association with pro-
longed steroid therapy, the patient then developed pulmonary 
zygomycetes from which he died 2 months later.
Effects of multiple doses of dimerizing drug on serial 
depletion of iC9-T cells
After the initial dose of dimerizing drug (dose #1; 3 months 
after the initial iC9-T–cell infusion), circulating CD3+CD19+ 
T cells decreased from 532/µl to 28/µlL within 2 hours 
(Figure 1a,b). Residual CD3+CD19+ T cells expanded over the 
next 3 months (Figure 1a), and on administration of the sec-
ond dose of dimerizing drug (#2), the circulating CD3+CD19+ 
T cells decreased from 220/µl to 78/µl; there was no substantive 
change in CD3+CD19+ T cells after the third dose of AP1903, 48 
hours later (Figure 1c).
Table 1 Viral reactivations and infections after iC9-T–cell infusion
Time to iC9-T–cell infusion AdV (copies/ml) CMV (copies/ml) HHV6 (copies/ml) BKV (copies/ml) EBV (copies/µg DNA)
Pre-infusion 3,000 228 0 12,300 0
Week 1 0 1,802 1,300 11,600 0
Week 2 0 1,537 <188 11,300 0
Week 3 0 318 0 29,000 0
Week 4 0 0 0 51,100 0
Week 5 0 0 0 107,000 0
Week 6 0 0 <188 69,500 0
Week 7 0 0 0 N/A 0
Week 8 0 0 0 26,800 0
Week 9 0 0 0 4,500 454
Week 10 0 0 0 0 4,267
Week 11 0 0 0 0 25,918b
Week 12 0 0 0 0 754
Month 3 (AP1903 #1) 0 0 0 0 105b
Month 3.5 0 0 <188 0 76
Month 4 0 0 0 0 0
Month 4.5 0 742a 0 0 0
Month 5 0 <50 0 0 0
Month 6 (AP1903 #2/#3) 0 0 0 0 0
Month 7 0 265 0 19,700 0
Month 8 0 93 0 6,600 0
aReactivation of CMV that was rapidly controlled without further treatment. bPatient received Rituximab.
AdV, adenovirus; BKV, BK virus; CMV, cytomegalovirus; Epstein–Barr virus; HHV6, human herpesvirus 6.
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Safety of multiple doses of dimerizing drug
There were no non-hematological toxicities associated with 
administration of any of the doses of AP1903. However, following 
each dose, there was a transient decrease of peripheral blood cell 
counts in all lineages. Figure  2 shows the effects of the dimer-
izer on nontransduced (CD3+CD19−) T cells after each treatment 
with the dimerizing drug; counts returned to pretreatment levels 
within 72 hours (Figure 2b,c). The drug had similar effects on B 
lymphocytes and natural killer (NK) cells (see Supplementary 
Figure S1) and on neutrophils and platelets (see Supplementary 
Figure S2). Overall, we observed a transient hematological toxic-
ity that was limited to grade 2.
Mechanism of iC9 T-cell resistance/recovery
A subpopulation of iC9+ T cells may persist after exposure to the 
dimerizing drug because the surviving cells express lower levels 
of the transgene. We therefore examined the level of iC9-ΔCD19 
expression in the T-cell population before and after each dimerizer 
treatment. Figure 3a shows the absolute number of CD3+CD19+ 
T cells detected in peripheral blood before each dimerizer treat-
ment. Immediately prior to the first exposure to dimerizing drug, 
the mean fluorescence intensity (MFI) of CD19 in iC9-T cells was 
12,200 (Figure 3b left panel). The recovering iC9+ cells, however, 
had a lower MFI, so that immediately prior to the second treat-
ment, the value was 4,419. The cells surviving from the second 
treatment had still lower median expression, so that immediately 
prior to treatment 3 the MFI was just 2,605 (Figure 3b left panel). 
Of note, immediately following dimerizer treatment, the MFI of 
surviving cells was always less than 3,000, irrespective of the num-
ber of prior drug exposures (Figure 3b right panel), meaning that 
the highest expressing fraction of cells (>3,000 MFI) is removed 
at each drug exposure. Consistent with selective removal of the 
highest expressing cells, the iC9 transgene copy number detected 
before and after each dimerizer treatment by quantitative PCR 
(Q-PCR) showed a 90% decline after the first dimerizer treatment 
(from 11.5 to 1.1, normalized by β-actin), but limited further 
decline after exposure #2 and no discernible additional fall after 
exposure #3 (see Supplementary Figure S3). Hence, differences 
in the proportion of cells eliminated after each dose relate to a 
progressive destruction of the most highly transduced and most 
highly expressing cells.
Lower levels of iC9 expression also reflect reduced 
T-cell activation
Although iC9 selectively eliminated the most highly expressing 
and most highly transduced T cells, the susceptibility to dimeriz-
ing drug may be further influenced by the activation status of the 
T cells. Transgene expression derived from retroviral integrants 
is highly dependent on the state of T-cell activation;16–18 during 
GvHD, for example, alloreactive cells are the most activated, 
express the highest level of iC9, and therefore are the most read-
ily eliminated.10 To determine whether the reduced iC9-CD19 
Figure 1 Detection of circulating iC9-T cells before and after dimerizer treatment. (a) Counts of circulating iC9-T cells after infusion. Red line with 
filled circle represents CD3+CD19+ T cells, green dashed line with square represents CD4+CD19+ T cells, and blue line with empty triangle represents 
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expression observed during subsequent exposure to dimerizing 
drug also correlated with the level of activation of the residual 
transduced T cells, we measured CD25 positivity in the T-cell 
population (Figure 4). All CD8+CD19+CD25+ T cells were elimi-
nated after the first dimerizer treatment (18/µl and 0/µl, pre and 
post treatment, respectively) and, in contrast to the bulk popu-
lation of T cells, had not returned in the 3 months prior to the 
second treatment (Figure  4a). Similarly, more than 90% of the 
CD4+CD19+CD25+ T-cell population was eliminated after the first 
dimerizer treatment (48/µl to 4/µl, pre and post treatment, respec-
tively) and had minimal re-expansion during the next 3 months 
(10/µl and 7/µl, pre and post treatment, respectively) (Figure 4b).
To further assess whether the reduced in vivo destruction of 
T  cells after subsequent doses of the dimerizing agent predomi-
nantly reflected the lack of associated in vivo (allo)activation by 
GvHD, we collected T cells from the patient after his GvHD had 
been treated with dimerizing drug. These T cells were then exposed 
in vitro to CD3/CD28 monoclonal antibodies to simulate T-cell 
receptor (TCR) activation and co-stimulation. At 48–72 hours, 
CD3/CD28 reactivated CD3+CD19+ cells had significantly higher 
transgene expression than nonreactivated cells, with their CD19 
MFI increasing from 4,603 to 30,720 (CD19+), while their CD3 MFI 
was unchanged (Figure  5a). Following exposure to CD3/CD28, 
we treated these cells with CID, and the percentage of CD3+CD19+ 
cells surviving exposure to CID was reduced by half, from 18 to 8% 
(Figure 5b). Killing of CD3+CD19− T cells following CID exposure 
was unaffected by prior anti-CD3/anti-CD28 activation (Figure 5c).
Screening for mutations of the iC9 transgene
To evaluate whether resistance arose from functional mutations 
in the iC9 protein, we sequenced the iC9 transgene obtained 
after amplification of the DNA extracted from total peripheral 
blood mononuclear cells (PBMCs) collected at different time 
points before and after AP1903 treatments. We sequenced mul-
tiple individual clones derived from the subcloned PCR products. 
Nonsense mutations causing a premature stop codon in the iC9 
transgene were detected in 2 out of 10 and 1 out of 10 subcloned 
PCR products in the DNA extracted from PBMCs collected 30 
minutes and 4 days after the third administration of AP1903, 
respectively (Figure 6). Hence, sporadic mutations could contrib-
ute to the low responses but they are neither the sole nor the pri-
mary mechanism for dimerizer resistance.
DISCUSSION
Rapid control or elimination of cells expressing a therapeu-
tic transgene may be required to overcome both short- and 
 long-term toxicities.19–22 We have previously shown that the 
iC9 safety system can be activated by a single dose of 0.4 mg/kg 
AP1903, and iC9 activation can effectively and sustainably 
remove alloreactive T cells causing GvHD after haplo-HSCT. 
The system can immediately control the symptoms and signs 
of a systemic inflammatory response associated with T-cell 
 activation.14,15–23 In the current report, we show that additional 
dimerizer treatments can eliminate up to 85% of the iC9- 
resistant T cells that survive after the first dose of dimerizer 
Figure 2 Counts of circulating CD3+CD19− T cells. (a) Counts of circulating endogenous T cells after iC9-T–cell infusion. Red line with filled circle 
represents CD3+CD19− T cells, green dashed line with square represents CD4+CD19− T cells, and blue line with empty triangle represents CD8+CD19− 
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Figure 3 The expression of CD19 on iC9-T cells at each treatment. (a) Flow analysis shows iC9-T cells prior to and post each dimerizer treatment, 



















































































Figure 4 Activated T cells before and after dimerizer treatment. Count of circulating (a) CD8+CD19+CD25+ T cells; (b) CD4+CD19+CD25+ T cells; 
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drug. In circumstances where persistence or regrowth of adop-
tively transferred T cells may be problematic, the administra-
tion of multiple doses of dimerizing drug appears to be safe and 
to induce further T-cell depletion.
A number of safety concerns are associated with adop-
tive T-cell therapies. Adverse effects include the acute toxicities 
of GvHD after transfer of allogeneic T cells2,12,15 and a cytokine 
release syndrome (or systemic inflammatory response) when 
adoptively transferred T cells become highly activated and expand 
in vivo, producing pro-inflammatory cytokines and inducing the 
release of additional inflammatory mediators from monocytes and 
other cells.4,24–26 In addition to these complications, there may be 
 off-target damage to unrelated cells. For instance, fatal neurologic 
and cardiac toxicities can be caused by the cross-reactivity of high-
affinity MAGE-A3 TCR with unrecognized expression of epitopes, 
even unrelated peptides in off-target organs or tissues.7,27,28 Finally, 
there may be on-target but off-tumor organ toxicities such as the 
hypogammaglobulinemia that follows the prolonged depletion of 
normal CD19+ B cells by long-lived  CD19-CAR T cells intended 
to kill CD19+ malignancies.20
Figure 5 Transgene expression could be upregulated by reactivation in vitro and makes the cells more sensitive to the dimerizer. (a) The expres-
sion of CD19 significantly increased (left panel) after ex vivo activation by OKT3/anti-CD28 antibody and CD3 (right panel), black line indicates the 
expression in peripheral blood and blue line indicates the expression in T cells reactivated by OKT3/anti-CD28. (b) In vitro drug sensitivity in CD3+CD19+ 
T cells with or without OKT3/anti-CD28 reactivation and (c) in vitro drug sensitivity in CD3+CD19− populations. The percentage indicates the live cells 






























100 101 102 103
AnnV




























No CID CID (10 nmol/l)















828 www.moleculartherapy.org vol. 24 no. 4 apr. 2016
© The American Society of Gene & Cell Therapy
Sequential Activation of the Inducible Caspase 9 Gene
We have previously shown that a single dose of dimerizing 
drug produces sufficient iC9 activation to rapidly deplete adop-
tively transferred haploidentical donor T cells and to rapidly and 
completely resolve the symptoms and signs of GvHD. Importantly, 
this single-dose regimen is sufficient to permanently abrogate 
the GvHD even though a small number of remaining (in vivo 
 dimerizer-resistant) T cells subsequently expand and repopulate 
the host, likely because these cells have been depleted of their allo-
reactive component. In other applications of adoptive T-cell ther-
apy, however, resurgent T cells might again produce the adverse 
effects initially observed, including the elimination of CD19+ nor-
mal B cells by CD19-CAR T cells. The outcome we report here 
is the first to show that such resistant and then resurgent T cells 
nonetheless continue to be vulnerable to killing by re-exposure to 
additional doses of the dimerizing drug in vivo, although the level 
of killing is lower than on initial exposure (85 versus 95%).
One concern over repeated administration of dimerizing drug 
is that there may be unexpected toxicities. Although no evidence 
of treatment-related serious adverse events was reported in large 
animal models exposed either to a higher dosage of dimerizing 
drug for 30 days consecutively or to long-term administration of 
the agent,29,30 there are no phase 1 data to show that multidose 
administration is safe in humans.31 Our patient had evidence of 
liver toxicity after the first dose of AP1903, but we think this was 
likely not associated with CID administration since the onset 
was delayed and did not worsen with subsequent drug treat-
ments. Moreover, no such toxicity was reported in a phase 1 
study of single-dose administration of the dimerizing drug even 
when a higher dose was infused (1.0 mg/kg versus 0.4 mg/kg); of 
note, none of the seven other patients treated with the agent had 
hepatotxicity attributable to drug administration.12,14,15 We did, 
however, observe one potentially related toxicity in this patient, 
a mild and transient pancytopenia (grade 2) that was present 
immediately after each administration of AP1903 and resolved 
within 72 hours. This response was not observed in preclinical 
testing, or in the phase 1 study, or in any of seven other patients 
we treated. We do not know the mechanism underlying this idio-
syncratic reaction, but since it lasted less than 72 hours after each 
administration of the drug we believe it is less likely attributable to 
direct toxicity to marrow or blood cells.
Although additional doses of the dimerizing drug continued 
to deplete T cells, a small proportion of iC9-T cells survived even 
after three treatments. Clinical studies using the herpes simplex 
virus thymidine kinase (HSV-TK) suicide gene system showed that 
more than 10% of the transduced T lymphocytes were resistant 
to killing even after multiple doses of ganciclovir.32 Although nei-
ther iC9 or HSV-TK can produce 100% elimination of transduced 
cells, the iC9 system may have advantages over HSV-TK. The iC9 
system can control a broader range of toxicities from adoptively 
transferred T cells since it is activated by a drug that is otherwise 
bioinert rather than a therapeutically efficacious prodrug such as 
ganciclovir, and may be preferable for the treatment of some of the 
acute adverse events associated with adoptive transfer of T cells 
as the speed of action is faster. iC9 may also be less immunogenic 
than HSV-TK in immunocompetent T-cell recipients23 and there-
fore less likely to lead to unwanted elimination of the T cells, but 
this remains to be established.
While the ability to repeatedly reduce T-cell numbers may pro-
vide adequate control of many adverse events, some will require 
complete elimination of the transferred cells. Multiple mechanisms 
Figure 6 Mutations detected in DNA after the third dimerizer treatment. iC9 transgene was amplified from the DNA extracted from peripheral 
blood mononuclear cells collected after the third administration of AP1903; multiple individual clones derived from the subcloned polymerase chain 
reaction products were sequenced. Nonsense mutations that generated a premature stop codon in the transgene at amino acid 61 were detected 
in the 2 out of 10 DNA samples and 1 out of 10 sample obtained 30 minutes and 4 days post #3 treatment, respectively (indicated in the red box). 
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may contribute to dimerizer resistance of iC9-T cells, such as 
selection of a subset of T cells with proviral integration sites that 
favor low gene expression, transgene silencing by promoter hyper-
methylation, or constitutively high expression of  anti-apoptotic 
proteins.18,33–38 Our earlier studies suggested that high levels of 
transcription of the iC9 transgene caused by TCR activation in 
alloreactive T cells explain the selective elimination of these cells 
by the dimerizer in patients who have clinical evidence of acute 
GvHD. Here, we found that surviving iC9-T cells continue to be 
eliminated by subsequent and delayed doses of the same drug. 
Although we cannot formally conclude that the iC9-T cell clones 
spared by the first dose of AP1903 are eliminated by subsequent 
doses of the drug, the continuous elimination of iC9-T cells may 
reflect dynamic changes in the levels of iC9 expression in vivo. This 
explanation reflects the existence either of alloreactive T cells with 
different thresholds for TCR activation or T cells that respond to 
other environmental factors in the infused polyclonal iC9-T cells. 
After the first dose of AP1903, residual alloreactive T cells with low 
TCR affinity and T cells responding to homeostatic stimuli rather 
than alloreactive antigens may emerge and become activated to 
express sufficient levels of iC9 to be eliminated by subsequent doses 
of AP1903. Although sporadic nonsense mutations of the iC9 trans-
gene were observed, their frequency is too low for them to contrib-
ute substantively to the partial dimerizer resistance observed.
In conclusion, we show the feasibility, safety, and efficacy of serial 
activation of the iC9 safety switch, which may enable toxicities asso-
ciated with the adoptive transfer of T cells to be sustainably reduced. 
It remains to be elucidated whether alternative vector design, such as 
the introduction of internal potent promoters into lentiviral vectors, 
or specific gene editing may allow higher constitutive expression of 
the iC9 transgene and even higher levels of sustained elimination of 
transgenic cells, should such activity be necessary.39,40
MATERIALS AND METHODS
Patients and study design. This phase 1 clinical study was conducted 
in accordance with the Declaration of Helsinki and was approved by the 
institutional review board of Baylor College of Medicine. This trial was 
registered at www.clinicaltrials.gov as NCT01494103. The study was 
designed to assess the safety and efficacy of infusing escalating doses of 
 donor-derived iC9-T cells in patients undergoing haplo-HSCT using 
Clinimacs selected CD34+ stem cells from an human leukocyte antigen 
haploidentical donor. Briefly, the patient reported here received iC9-T 
cells at day 47 after transplant at a dose of 1 × 106 cells/kg as previously 
described.15 The patient received three doses of AP1903 (0.4 mg/kg) at 
day 89, 175, and 178 after the infusion of iC9-T cells to deplete the iC9-T 
cells associated adverse events, the administration of AP1903 (Rimiducid, 
Bellicum Pharmaceuticals, Houston, TX) as 2-hour infusion.31
Monitoring of infections. Viral (AdV, BKV, CMV, and HHV6) reactivation 
or infections were monitored by Q-PCR assays (ViraCor-IBT Laboratories, 
Lee’s Summit, MO) on plasma as noted. EBV-DNA viral load was deter-
mined by Q-PCR of PBMCs using specific primers and probes targeting 
the EBER gene.41
Generation of iC9-T cells. The iC9-T cells were generated as previously 
described.15 In brief, PBMCs from transplant donors were obtained by 
Ficoll density before they were activated by anti-CD3 antibody. Gene mod-
ification with iC9 followed the previously reported procedure.15
Flow cytometry analysis. The iC9-T cells were characterized using a panel of 
fluorochrome-conjugated monoclonal antibodies (BD Biosciences, San Jose, 
CA and Beckman Coulter, Brea CA). Cells were acquired on a FACS Calibur 
flow cytometer. Nontransduced control cells were used to set the negative 
gate for CD19 expression. Flow cytometry data were analyzed using Cell 
Quest software (Becton Dickinson) and Kaluza software (Beckman Coulter).
Real-time quantitative PCR of iC9.T2A.ΔCD19 transgene. The iC9 trans-
gene was measured in PBMCs by Q-PCR as previously described.12,14,15
Assessment of transgene expression following reactivation. The PBMCs 
were collected after treatment of AP1903, a portion of the cells were reacti-
vated on 24-well plates coated with 1 µg/ml OKT3 and 1 µg/ml anti-CD28 
(Clone CD28.2, BD Pharmingen, San Diego, CA) for 48–72 hours. CD19 
expression in both reactivated and nonreactivated cells were evaluated by 
flow cytometry and Q-PCR.
Induction of apoptosis with CID. Suicide gene functionality was assessed 
by CID (AP20187, Clontech Laboratories, Mountain View, CA), at 10 nM 
final concentration. Cells were stained with annexin V and 7-amino-
actinomycin (7-AAD) (BD Pharmingen) for 22–30 hours and analyzed 
by flow cytometry. Cells negative for both annexin V and 7-AAD were 
considered viable, cells that were annexin V positive were apoptotic, and 
cells that were both annexin V and 7-AAD positive were necrotic. The per-
centage killing induced by dimerization was corrected for baseline viability 
as follows: Percentage killing = 100 − (%Viability in CID-treated cells ÷ 
%Viability in nontreated cells) × 100.
Screening for mutations of the iC9 transgene. DNA was extracted from 
PBMCs at different time points before and after AP1903 treatments. The 
iC9 transgene was amplified by high fidelity PCR and subcloned into 
the TOPO Blunt-End vector (ThermoFisher Scientific, Waltham, MA). 
The sequence of the primers used for amplification was forward 5′- 
TGTGGGTCAGAGAGCCAAAC -3′, reverse 5′- ctgcagcacagcgttatctc -3′. 
For each time point, we sequenced the iC9 transgene from DNA plasmid 
obtained from multiple individual subcloned colonies.
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Figure S1. Counts of circulating B cells and NK cells.
Figure S2. Counts of neutrophil and platelets at each dimerizer 
treatment.
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of DNA obtained from PBMCs, evaluated by Q-PCR.
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